Is ADMA Biologics (ADMA) Outperforming Other Medical Stocks This Year?

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Adma Biologics (ADMA) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

Adma Biologics is a member of the Medical sector. This group includes 948 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.

The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Adma Biologics is currently sporting a Zacks Rank of #2 (Buy).

Over the past 90 days, the Zacks Consensus Estimate for ADMA's full-year earnings has moved 1.6% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.

According to our latest data, ADMA has moved about 6.8% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 6.4% on a year-to-date basis. This means that Adma Biologics is outperforming the sector as a whole this year.

One other Medical stock that has outperformed the sector so far this year is Cronos Group (CRON). The stock is up 20.8% year-to-date.

For Cronos Group, the consensus EPS estimate for the current year has increased 87.5% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).

Looking more specifically, Adma Biologics belongs to the Medical - Biomedical and Genetics industry, a group that includes 467 individual stocks and currently sits at #87 in the Zacks Industry Rank. On average, this group has gained an average of 17.8% so far this year, meaning that ADMA is slightly underperforming its industry in terms of year-to-date returns.

Cronos Group, however, belongs to the Medical - Drugs industry. Currently, this 144-stock industry is ranked #69. The industry has moved +6.2% so far this year.

Going forward, investors interested in Medical stocks should continue to pay close attention to Adma Biologics and Cronos Group as they could maintain their solid performance.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research